{"gene":"ZNF655","run_date":"2026-06-11T09:02:07","timeline":{"discoveries":[{"year":2005,"finding":"VIK-1 (ZNF655) was identified as a Vav-1 binding partner via two-hybrid screening of a Jurkat cell cDNA library. VIK-1 interacts with Vav-1 through its SH3 domain and independently interacts with cyclin-dependent kinase 4 (CDK4) through a separate domain. VIK-1 shuttles between nucleus and cytoplasm via functional nuclear localization and export sequences, is expressed during G1 phase, and its overexpression inhibits cell-cycle progression in a manner reversed by Vav-1 co-expression.","method":"Yeast two-hybrid screening, Co-IP, subcellular localization (nuclear/cytoplasmic shuttling assay), cell-cycle analysis (flow cytometry), overexpression/rescue experiments","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal interactions confirmed by two-hybrid and Co-IP, two orthogonal methods (binding + functional cell-cycle assay), single lab","pmids":["15558030"],"is_preprint":false},{"year":2022,"finding":"ZNF655 promotes pancreatic cancer progression by facilitating the binding of transcription factor E2F1 to the CDK1 promoter. ChIP and dual-luciferase reporter assays demonstrated direct ZNF655-dependent E2F1 occupancy at the CDK1 promoter. CDK1 knockdown reversed the pro-tumorigenic effects of ZNF655 overexpression, placing ZNF655 upstream of CDK1 in a transcriptional regulatory axis.","method":"Co-immunoprecipitation (Co-IP), chromatin immunoprecipitation (ChIP), dual-luciferase reporter assay, loss/gain-of-function assays in vitro and in vivo","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (Co-IP, ChIP, luciferase, rescue), single lab","pmids":["35927248"],"is_preprint":false},{"year":2022,"finding":"ZNF655 acts as a transcription factor that directly binds to the AURKA (Aurora kinase A) promoter and activates its transcription in glioma cells. ChIP-qPCR confirmed ZNF655 occupancy at the AURKA promoter, and luciferase reporter assays confirmed transcriptional activation. Downregulation of AURKA partially reversed the pro-tumorigenic effects of ZNF655 overexpression.","method":"Chromatin immunoprecipitation (ChIP)-qPCR, dual-luciferase reporter assay, shRNA knockdown, rescue experiments","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase reporter are orthogonal methods confirming direct promoter binding, single lab","pmids":["35280721"],"is_preprint":false},{"year":2020,"finding":"ZNF655 functions as a transcriptional regulator that binds to the ANKHD1 promoter region, forming part of an ANKHD1/LINC00346/ZNF655 feedback loop in glioma-associated endothelial cells. LINC00346 promotes degradation of ZNF655 mRNA via Staufen1 (STAU1)-mediated mRNA decay (SMD) through Alu element base-pairing, placing ZNF655 as a downstream target of this lncRNA-mediated regulatory circuit.","method":"Luciferase reporter assay (promoter binding), RNA immunoprecipitation (RIP), STAU1 knockdown, overexpression/knockdown functional assays, in vivo angiogenesis model","journal":"Molecular therapy. Nucleic acids","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIP and luciferase reporter as orthogonal methods, single lab, functional rescue included","pmids":["32464549"],"is_preprint":false},{"year":2023,"finding":"ZNF655 promotes hepatocellular carcinoma (HCC) progression through PSMB8 (proteasome subunit beta type-8). Co-expression of ZNF655 and PSMB8 was identified in HCC, and PSMB8 knockdown attenuated the pro-tumorigenic effects of ZNF655 overexpression, indicating PSMB8 is a downstream effector of ZNF655 in HCC.","method":"Loss/gain-of-function assays, rescue experiments (PSMB8 knockdown in ZNF655-overexpressing cells), in vitro and in vivo tumor models","journal":"Cell biology international","confidence":"Low","confidence_rationale":"Tier 3 / Weak — functional rescue experiments establish downstream relationship but no direct binding or transcriptional mechanism demonstrated; single lab, single approach","pmids":["37272200"],"is_preprint":false},{"year":2024,"finding":"ZNF655 promotes multiple myeloma (MM) progression via activation of AKT signaling. ZNF655 knockdown inhibited MM cell proliferation, arrested the cell cycle, and induced apoptosis, with mechanistic evidence linking ZNF655 to AKT pathway regulation.","method":"Loss-of-function assays in vitro and in vivo, Western blotting for AKT pathway components","journal":"Cell biology international","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pathway placement inferred from knockdown phenotype and western blot, no direct binding or upstream mechanism established","pmids":["39491549"],"is_preprint":false},{"year":2025,"finding":"ZNF655 exerts neuroprotective effects against OGD/R-induced injury by activating the Akt/Nrf2 signaling pathway. ZNF655 overexpression promoted Akt phosphorylation and facilitated Nrf2 nuclear translocation, upregulating downstream antioxidant genes. Pharmacological inhibition of Akt or Nrf2 silencing attenuated ZNF655's protective effects, placing ZNF655 upstream of Akt/Nrf2.","method":"Adenoviral overexpression, immunoblotting, RT-qPCR, CCK-8 cell viability assay, TUNEL apoptosis assay, ELISA, pharmacological inhibition (Akt inhibitor), Nrf2 siRNA knockdown","journal":"Brain research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pathway placement by pharmacological inhibition and knockdown; no direct binding mechanism between ZNF655 and Akt established","pmids":["41352639"],"is_preprint":false},{"year":2025,"finding":"ZNF655 facilitates nuclear translocation of MAFF transcription factor in ovarian cancer cells, leading to MAFF's direct binding to the CCND1 (Cyclin D1) promoter and transcriptional activation of CCND1. Rescue experiments showed CCND1 mediates ZNF655-dependent proliferation and stemness. ZNF655 overexpression conferred paclitaxel resistance in ovarian cancer cells.","method":"Nuclear fractionation/translocation assay (MAFF nuclear translocation), ChIP (MAFF binding to CCND1 promoter), rescue experiments, in vitro and in vivo (xenograft) functional assays","journal":"Cancer cell international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and nuclear translocation assay provide orthogonal mechanistic evidence; single lab","pmids":["41088232"],"is_preprint":false}],"current_model":"ZNF655 (VIK-1) is a Krüppel-like C2H2 zinc finger protein that functions primarily as a transcriptional regulator: it directly binds gene promoters (AURKA, ANKHD1, CCND1 via MAFF) to activate transcription, interacts with Vav-1 and CDK4 to modulate G1 cell-cycle progression, activates AKT/Nrf2 signaling, and promotes E2F1 binding to the CDK1 promoter, collectively driving cell proliferation and cancer progression across multiple tumor types."},"narrative":{"mechanistic_narrative":"ZNF655 (VIK-1) is a Krüppel-like C2H2 zinc finger protein that operates as a nucleocytoplasmic transcriptional regulator coordinating cell-cycle progression and proliferative signaling [PMID:15558030, PMID:35927248]. It was first defined through its physical interactions: it binds the Vav-1 SH3 domain and, through a separate domain, cyclin-dependent kinase 4 (CDK4), is expressed during G1 phase, and shuttles between nucleus and cytoplasm via functional nuclear localization and export sequences [PMID:15558030]. As a sequence-specific transcriptional activator it directly occupies and drives transcription from target promoters, including the AURKA promoter in glioma [PMID:35280721] and, via facilitated nuclear translocation of the MAFF transcription factor, the CCND1 (Cyclin D1) promoter in ovarian cancer [PMID:41088232]. ZNF655 also promotes E2F1 occupancy at the CDK1 promoter, placing it upstream of a CDK1-dependent proliferative axis in pancreatic cancer [PMID:35927248]. Across multiple tumor types these activities converge on enhanced proliferation and cancer progression, and ZNF655 is itself subject to feedback control as a downstream target of an ANKHD1/LINC00346 circuit in which LINC00346 triggers Staufen1-mediated decay of ZNF655 mRNA [PMID:32464549].","teleology":[{"year":2005,"claim":"Established ZNF655/VIK-1 as a cell-cycle-associated protein by identifying its direct binding partners and its regulated subcellular distribution, framing it as a G1-phase modulator rather than an orphan zinc finger.","evidence":"Yeast two-hybrid screen of a Jurkat cDNA library, Co-IP, nuclear/cytoplasmic shuttling assay, and overexpression/rescue cell-cycle analysis","pmids":["15558030"],"confidence":"Medium","gaps":["No DNA-binding target or direct transcriptional output identified at this stage","Functional consequence of CDK4 binding not mechanistically resolved","Endogenous role versus overexpression phenotype not distinguished"]},{"year":2020,"claim":"Placed ZNF655 within a regulatory feedback circuit, showing it both binds the ANKHD1 promoter and is post-transcriptionally controlled by LINC00346 via Staufen1-mediated mRNA decay, demonstrating the gene is itself a regulated node.","evidence":"Luciferase promoter-binding assay, RIP, STAU1 knockdown, and in vivo angiogenesis model in glioma-associated endothelial cells","pmids":["32464549"],"confidence":"Medium","gaps":["Direct sequence-specific binding of ZNF655 protein to the ANKHD1 promoter not structurally defined","Generality of the feedback loop beyond endothelial cells unknown"]},{"year":2022,"claim":"Defined ZNF655 as a direct transcriptional activator by demonstrating promoter occupancy and reporter activation at AURKA, and showed it promotes E2F1 loading at the CDK1 promoter, identifying concrete downstream proliferative effectors.","evidence":"ChIP-qPCR and dual-luciferase reporter assays plus rescue (AURKA in glioma); Co-IP, ChIP, luciferase and CDK1-knockdown rescue (E2F1/CDK1 in pancreatic cancer)","pmids":["35280721","35927248"],"confidence":"Medium","gaps":["Consensus DNA-binding motif for ZNF655 not determined","Whether ZNF655 binds CDK1 promoter directly or only enables E2F1 recruitment not fully resolved"]},{"year":2025,"claim":"Extended the activation mechanism to a co-factor mode, showing ZNF655 drives CCND1 transcription by facilitating nuclear translocation of MAFF, linking ZNF655 to cyclin D1-dependent proliferation, stemness, and chemoresistance.","evidence":"Nuclear translocation assay, ChIP for MAFF at the CCND1 promoter, and rescue plus xenograft assays in ovarian cancer","pmids":["41088232"],"confidence":"Medium","gaps":["Mechanism by which ZNF655 promotes MAFF nuclear import not defined","Whether ZNF655 itself contacts the CCND1 promoter not established"]},{"year":2025,"claim":"Implicated ZNF655 in AKT-axis signaling across malignant and neuroprotective contexts, linking it to AKT and Akt/Nrf2 antioxidant pathway activation, though without a direct binding mechanism.","evidence":"Loss/gain-of-function assays with immunoblotting in multiple myeloma; adenoviral overexpression, pharmacological Akt inhibition, and Nrf2 siRNA in an OGD/R neuronal injury model","pmids":["39491549","41352639"],"confidence":"Low","gaps":["No direct physical link between ZNF655 and AKT or Nrf2 demonstrated","Pathway placement inferred from inhibitor/knockdown phenotypes only","Single lab per context, not independently confirmed"]},{"year":null,"claim":"The DNA-binding specificity, direct genomic targets, and structural basis by which ZNF655 selects promoters versus acting through partner transcription factors remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No genome-wide binding map or consensus motif for ZNF655","Distinction between direct promoter binding and co-factor/translocation roles not systematically tested","No structural data on the zinc finger array"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,2,3,7]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[2,3]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,7]}],"complexes":[],"partners":["VAV1","CDK4","E2F1","MAFF"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8N720","full_name":"Zinc finger protein 655","aliases":["Vav-interacting Krueppel-like protein"],"length_aa":491,"mass_kda":57.4,"function":"Probable transcription factor","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8N720/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZNF655","classification":"Not Classified","n_dependent_lines":10,"n_total_lines":1208,"dependency_fraction":0.008278145695364239},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"INTS14","stoichiometry":4.0},{"gene":"POLR2K","stoichiometry":0.2},{"gene":"SSRP1","stoichiometry":0.2},{"gene":"SUPT5H","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ZNF655","total_profiled":1310},"omim":[{"mim_id":"617891","title":"ZINC FINGER PROTEIN 655; ZNF655","url":"https://www.omim.org/entry/617891"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ZNF655"},"hgnc":{"alias_symbol":["VIK-1","VIK"],"prev_symbol":[]},"alphafold":{"accession":"Q8N720","domains":[{"cath_id":"3.30.160.60","chopping":"211-264","consensus_level":"medium","plddt":76.6765,"start":211,"end":264},{"cath_id":"3.30.160.60","chopping":"300-351","consensus_level":"medium","plddt":67.8765,"start":300,"end":351},{"cath_id":"3.30.160.60","chopping":"379-454","consensus_level":"medium","plddt":65.798,"start":379,"end":454}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N720","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N720-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N720-F1-predicted_aligned_error_v6.png","plddt_mean":53.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZNF655","jax_strain_url":"https://www.jax.org/strain/search?query=ZNF655"},"sequence":{"accession":"Q8N720","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8N720.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8N720/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N720"}},"corpus_meta":[{"pmid":"19000166","id":"PMC_19000166","title":"VH1/BRL2 receptor-like kinase interacts with vascular-specific adaptor proteins VIT and VIK to influence leaf venation.","date":"2008","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19000166","citation_count":58,"is_preprint":false},{"pmid":"32464549","id":"PMC_32464549","title":"Role of ANKHD1/LINC00346/ZNF655 Feedback Loop in Regulating the Glioma Angiogenesis via Staufen1-Mediated mRNA Decay.","date":"2020","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/32464549","citation_count":37,"is_preprint":false},{"pmid":"8380921","id":"PMC_8380921","title":"The murine vik gene (chromosome 9) encodes a putative receptor with unique protein kinase motifs.","date":"1993","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8380921","citation_count":22,"is_preprint":false},{"pmid":"28554562","id":"PMC_28554562","title":"Identification and pathotypical analysis of a novel VIk sub-genotype Newcastle disease virus obtained from pigeon in China.","date":"2017","source":"Virus research","url":"https://pubmed.ncbi.nlm.nih.gov/28554562","citation_count":20,"is_preprint":false},{"pmid":"15558030","id":"PMC_15558030","title":"Characterization of VIK-1: a new Vav-interacting Kruppel-like protein.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15558030","citation_count":18,"is_preprint":false},{"pmid":"35927248","id":"PMC_35927248","title":"ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1.","date":"2022","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/35927248","citation_count":17,"is_preprint":false},{"pmid":"34144060","id":"PMC_34144060","title":"ZNF655 is involved in development and progression of non-small-cell lung cancer.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34144060","citation_count":10,"is_preprint":false},{"pmid":"37272200","id":"PMC_37272200","title":"ZNF655 promotes the progression of hepatocellular carcinoma through PSMB8.","date":"2023","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/37272200","citation_count":8,"is_preprint":false},{"pmid":"35280721","id":"PMC_35280721","title":"ZNF655 Promotes the Progression of Glioma Through Transcriptional Regulation of AURKA.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35280721","citation_count":8,"is_preprint":false},{"pmid":"36519409","id":"PMC_36519409","title":"ZNF655 mediated by LINC01210/miR-124-3p axis promotes the progression of gastric cancer.","date":"2022","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36519409","citation_count":5,"is_preprint":false},{"pmid":"39491549","id":"PMC_39491549","title":"ZNF655 involved in the progression of multiple myeloma via the activation of AKT.","date":"2024","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/39491549","citation_count":1,"is_preprint":false},{"pmid":"41352639","id":"PMC_41352639","title":"ZNF655-mediated neuroprotection in cerebral ischemia-reperfusion injury via Akt/Nrf2 pathway modulation.","date":"2025","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/41352639","citation_count":1,"is_preprint":false},{"pmid":"40576591","id":"PMC_40576591","title":"Regulation of the immunity-related VIK-APK-EDS1 pathway in Medicago for resistance to Phytophthora.","date":"2025","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/40576591","citation_count":0,"is_preprint":false},{"pmid":"41088232","id":"PMC_41088232","title":"ZNF655 promotes tumor growth and chemoresistance by targeting MAFF-CCND1 axis in ovarian cancer.","date":"2025","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/41088232","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":8799,"output_tokens":2296,"usd":0.030419,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9380,"output_tokens":2442,"usd":0.053975,"stage2_stop_reason":"end_turn"},"total_usd":0.084394,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"VIK-1 (ZNF655) was identified as a Vav-1 binding partner via two-hybrid screening of a Jurkat cell cDNA library. VIK-1 interacts with Vav-1 through its SH3 domain and independently interacts with cyclin-dependent kinase 4 (CDK4) through a separate domain. VIK-1 shuttles between nucleus and cytoplasm via functional nuclear localization and export sequences, is expressed during G1 phase, and its overexpression inhibits cell-cycle progression in a manner reversed by Vav-1 co-expression.\",\n      \"method\": \"Yeast two-hybrid screening, Co-IP, subcellular localization (nuclear/cytoplasmic shuttling assay), cell-cycle analysis (flow cytometry), overexpression/rescue experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal interactions confirmed by two-hybrid and Co-IP, two orthogonal methods (binding + functional cell-cycle assay), single lab\",\n      \"pmids\": [\"15558030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZNF655 promotes pancreatic cancer progression by facilitating the binding of transcription factor E2F1 to the CDK1 promoter. ChIP and dual-luciferase reporter assays demonstrated direct ZNF655-dependent E2F1 occupancy at the CDK1 promoter. CDK1 knockdown reversed the pro-tumorigenic effects of ZNF655 overexpression, placing ZNF655 upstream of CDK1 in a transcriptional regulatory axis.\",\n      \"method\": \"Co-immunoprecipitation (Co-IP), chromatin immunoprecipitation (ChIP), dual-luciferase reporter assay, loss/gain-of-function assays in vitro and in vivo\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (Co-IP, ChIP, luciferase, rescue), single lab\",\n      \"pmids\": [\"35927248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZNF655 acts as a transcription factor that directly binds to the AURKA (Aurora kinase A) promoter and activates its transcription in glioma cells. ChIP-qPCR confirmed ZNF655 occupancy at the AURKA promoter, and luciferase reporter assays confirmed transcriptional activation. Downregulation of AURKA partially reversed the pro-tumorigenic effects of ZNF655 overexpression.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP)-qPCR, dual-luciferase reporter assay, shRNA knockdown, rescue experiments\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase reporter are orthogonal methods confirming direct promoter binding, single lab\",\n      \"pmids\": [\"35280721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZNF655 functions as a transcriptional regulator that binds to the ANKHD1 promoter region, forming part of an ANKHD1/LINC00346/ZNF655 feedback loop in glioma-associated endothelial cells. LINC00346 promotes degradation of ZNF655 mRNA via Staufen1 (STAU1)-mediated mRNA decay (SMD) through Alu element base-pairing, placing ZNF655 as a downstream target of this lncRNA-mediated regulatory circuit.\",\n      \"method\": \"Luciferase reporter assay (promoter binding), RNA immunoprecipitation (RIP), STAU1 knockdown, overexpression/knockdown functional assays, in vivo angiogenesis model\",\n      \"journal\": \"Molecular therapy. Nucleic acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIP and luciferase reporter as orthogonal methods, single lab, functional rescue included\",\n      \"pmids\": [\"32464549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZNF655 promotes hepatocellular carcinoma (HCC) progression through PSMB8 (proteasome subunit beta type-8). Co-expression of ZNF655 and PSMB8 was identified in HCC, and PSMB8 knockdown attenuated the pro-tumorigenic effects of ZNF655 overexpression, indicating PSMB8 is a downstream effector of ZNF655 in HCC.\",\n      \"method\": \"Loss/gain-of-function assays, rescue experiments (PSMB8 knockdown in ZNF655-overexpressing cells), in vitro and in vivo tumor models\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional rescue experiments establish downstream relationship but no direct binding or transcriptional mechanism demonstrated; single lab, single approach\",\n      \"pmids\": [\"37272200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ZNF655 promotes multiple myeloma (MM) progression via activation of AKT signaling. ZNF655 knockdown inhibited MM cell proliferation, arrested the cell cycle, and induced apoptosis, with mechanistic evidence linking ZNF655 to AKT pathway regulation.\",\n      \"method\": \"Loss-of-function assays in vitro and in vivo, Western blotting for AKT pathway components\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pathway placement inferred from knockdown phenotype and western blot, no direct binding or upstream mechanism established\",\n      \"pmids\": [\"39491549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZNF655 exerts neuroprotective effects against OGD/R-induced injury by activating the Akt/Nrf2 signaling pathway. ZNF655 overexpression promoted Akt phosphorylation and facilitated Nrf2 nuclear translocation, upregulating downstream antioxidant genes. Pharmacological inhibition of Akt or Nrf2 silencing attenuated ZNF655's protective effects, placing ZNF655 upstream of Akt/Nrf2.\",\n      \"method\": \"Adenoviral overexpression, immunoblotting, RT-qPCR, CCK-8 cell viability assay, TUNEL apoptosis assay, ELISA, pharmacological inhibition (Akt inhibitor), Nrf2 siRNA knockdown\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pathway placement by pharmacological inhibition and knockdown; no direct binding mechanism between ZNF655 and Akt established\",\n      \"pmids\": [\"41352639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZNF655 facilitates nuclear translocation of MAFF transcription factor in ovarian cancer cells, leading to MAFF's direct binding to the CCND1 (Cyclin D1) promoter and transcriptional activation of CCND1. Rescue experiments showed CCND1 mediates ZNF655-dependent proliferation and stemness. ZNF655 overexpression conferred paclitaxel resistance in ovarian cancer cells.\",\n      \"method\": \"Nuclear fractionation/translocation assay (MAFF nuclear translocation), ChIP (MAFF binding to CCND1 promoter), rescue experiments, in vitro and in vivo (xenograft) functional assays\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and nuclear translocation assay provide orthogonal mechanistic evidence; single lab\",\n      \"pmids\": [\"41088232\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZNF655 (VIK-1) is a Krüppel-like C2H2 zinc finger protein that functions primarily as a transcriptional regulator: it directly binds gene promoters (AURKA, ANKHD1, CCND1 via MAFF) to activate transcription, interacts with Vav-1 and CDK4 to modulate G1 cell-cycle progression, activates AKT/Nrf2 signaling, and promotes E2F1 binding to the CDK1 promoter, collectively driving cell proliferation and cancer progression across multiple tumor types.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ZNF655 (VIK-1) is a Krüppel-like C2H2 zinc finger protein that operates as a nucleocytoplasmic transcriptional regulator coordinating cell-cycle progression and proliferative signaling [#0, #1]. It was first defined through its physical interactions: it binds the Vav-1 SH3 domain and, through a separate domain, cyclin-dependent kinase 4 (CDK4), is expressed during G1 phase, and shuttles between nucleus and cytoplasm via functional nuclear localization and export sequences [#0]. As a sequence-specific transcriptional activator it directly occupies and drives transcription from target promoters, including the AURKA promoter in glioma [#2] and, via facilitated nuclear translocation of the MAFF transcription factor, the CCND1 (Cyclin D1) promoter in ovarian cancer [#7]. ZNF655 also promotes E2F1 occupancy at the CDK1 promoter, placing it upstream of a CDK1-dependent proliferative axis in pancreatic cancer [#1]. Across multiple tumor types these activities converge on enhanced proliferation and cancer progression, and ZNF655 is itself subject to feedback control as a downstream target of an ANKHD1/LINC00346 circuit in which LINC00346 triggers Staufen1-mediated decay of ZNF655 mRNA [#3].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established ZNF655/VIK-1 as a cell-cycle-associated protein by identifying its direct binding partners and its regulated subcellular distribution, framing it as a G1-phase modulator rather than an orphan zinc finger.\",\n      \"evidence\": \"Yeast two-hybrid screen of a Jurkat cDNA library, Co-IP, nuclear/cytoplasmic shuttling assay, and overexpression/rescue cell-cycle analysis\",\n      \"pmids\": [\"15558030\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No DNA-binding target or direct transcriptional output identified at this stage\", \"Functional consequence of CDK4 binding not mechanistically resolved\", \"Endogenous role versus overexpression phenotype not distinguished\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed ZNF655 within a regulatory feedback circuit, showing it both binds the ANKHD1 promoter and is post-transcriptionally controlled by LINC00346 via Staufen1-mediated mRNA decay, demonstrating the gene is itself a regulated node.\",\n      \"evidence\": \"Luciferase promoter-binding assay, RIP, STAU1 knockdown, and in vivo angiogenesis model in glioma-associated endothelial cells\",\n      \"pmids\": [\"32464549\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct sequence-specific binding of ZNF655 protein to the ANKHD1 promoter not structurally defined\", \"Generality of the feedback loop beyond endothelial cells unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined ZNF655 as a direct transcriptional activator by demonstrating promoter occupancy and reporter activation at AURKA, and showed it promotes E2F1 loading at the CDK1 promoter, identifying concrete downstream proliferative effectors.\",\n      \"evidence\": \"ChIP-qPCR and dual-luciferase reporter assays plus rescue (AURKA in glioma); Co-IP, ChIP, luciferase and CDK1-knockdown rescue (E2F1/CDK1 in pancreatic cancer)\",\n      \"pmids\": [\"35280721\", \"35927248\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Consensus DNA-binding motif for ZNF655 not determined\", \"Whether ZNF655 binds CDK1 promoter directly or only enables E2F1 recruitment not fully resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended the activation mechanism to a co-factor mode, showing ZNF655 drives CCND1 transcription by facilitating nuclear translocation of MAFF, linking ZNF655 to cyclin D1-dependent proliferation, stemness, and chemoresistance.\",\n      \"evidence\": \"Nuclear translocation assay, ChIP for MAFF at the CCND1 promoter, and rescue plus xenograft assays in ovarian cancer\",\n      \"pmids\": [\"41088232\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which ZNF655 promotes MAFF nuclear import not defined\", \"Whether ZNF655 itself contacts the CCND1 promoter not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Implicated ZNF655 in AKT-axis signaling across malignant and neuroprotective contexts, linking it to AKT and Akt/Nrf2 antioxidant pathway activation, though without a direct binding mechanism.\",\n      \"evidence\": \"Loss/gain-of-function assays with immunoblotting in multiple myeloma; adenoviral overexpression, pharmacological Akt inhibition, and Nrf2 siRNA in an OGD/R neuronal injury model\",\n      \"pmids\": [\"39491549\", \"41352639\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No direct physical link between ZNF655 and AKT or Nrf2 demonstrated\", \"Pathway placement inferred from inhibitor/knockdown phenotypes only\", \"Single lab per context, not independently confirmed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The DNA-binding specificity, direct genomic targets, and structural basis by which ZNF655 selects promoters versus acting through partner transcription factors remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No genome-wide binding map or consensus motif for ZNF655\", \"Distinction between direct promoter binding and co-factor/translocation roles not systematically tested\", \"No structural data on the zinc finger array\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 2, 3, 7]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"VAV1\", \"CDK4\", \"E2F1\", \"MAFF\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":5,"faith_total":5,"faith_pct":100.0}}